Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for Seattle Genetics Inc�
0.00 (0.00%)
Jun 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 30.05 - 49.84
Open     -
Vol / Avg. 0.00/878,448.00
Mkt cap 6.04B
P/E     -
Div/yield     -
EPS -0.66
Shares 124.89M
Beta 1.57
Inst. own 103%
Jul 30, 2015
Q2 2015 Seattle Genetics Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 1, 2015
Seattle Genetics Inc at Jefferies Global Healthcare Conference
May 19, 2015
Seattle Genetics Inc at UBS Global Healthcare Conference
May 15, 2015
Seattle Genetics Inc Annual Shareholders Meeting
May 14, 2015
Seattle Genetics Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Seattle Genetics Inc at Credit Suisse Antibody Day
May 6, 2015
Seattle Genetics Inc at Deutsche Bank Health Care Conference
Apr 30, 2015
Q1 2015 Seattle Genetics Inc Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Seattle Genetics Inc Earnings Release
Apr 15, 2015
Seattle Genetics Inc at Needham Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -26.40% -26.55%
Operating margin -26.47% -26.98%
EBITD margin - -22.62%
Return on average assets -19.22% -16.15%
Return on average equity -41.42% -34.53%
Employees 657 -
CDP Score - -


21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Company's pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics' sugar-engineered antibody (SEA) technology.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Todd E. Simpson Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 46
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Age: 53
Bio & Compensation  - Reuters
Vaughn B. Himes Ph.D. Executive Vice President - Technical Operations, Process Sciences
Age: 54
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 46
Bio & Compensation  - Reuters
John A. Orwin Director
Age: 50
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 59
Bio & Compensation  - Reuters